Outset Medical Q2 adjusted loss per share narrows less than expected
OM•Analyst coverage and price target
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 2 "strong buy" or "buy", 1 "hold" and no "sell" or "strong sell".
The average consensus recommendation for the advanced medical equipment and technology peer group is "buy". Wall Street's median 12-month price target for Outset Medical, Inc. is $7.00, about 36.7% above its August 5 closing price of $5.12.
Margins improve and outlook is reaffirmed
Gross margin expanded to 42%, up from 37.8% in the prior-year period.
Outset Medical reiterated 2026 revenue guidance of $125 million to $130 million and said it continues to expect full-year non-GAAP gross margin in the low-40% to mid-40% range.
Revenue mix and HCA agreement support results
Service and other revenue increased 17% year over year, offsetting a decline in product revenue.
The company also signed a three-year, $40 million agreement with HCA Healthcare to refresh Tablo systems.
